Papillomaviruses (PVs) are established agents of human and animal cancers. They infect cutaneous and mucous epithelia. High Risk (HR) Human PVs (HPVs) are consistently associated with cancer of the uterine cervix, but are also involved in the etiopathogenesis of other cancer types. The early oncoproteins of PVs: E5, E6 and E7 are known to contribute to tumour progression. While the oncogenic activities of E6 and E7 are well characterised, the role of E5 is still rather nebulous. The widespread causal association of PVs with cancer makes their study worthwhile not only in humans but also in animal model systems. The Bovine PV (BPV) system has been the most useful animal model in understanding the oncogenic potential of PVs due to the pivotal role of its E5 oncoprotein in cell transformation. This review will highlight the differences between HPV-16 E5 (16E5) and E5 from other PVs, primarily from BPV. It will discuss the targeting of E5 as a possible therapeutic agent.
Human papillomavirus (HPV) infection is emerging as a major prognostic and predictive marker in head and neck squamous cell carcinoma (HNSCC). Researches are focused on the development of HPV detection assays specially designed for HNSCC. The HPV diagnosis in these tumours is relevant toprognosis even in an already-developed tumour, whereas in the cervix, where the HPV is the cause of almost all tumours, this information has less clinical relevance. The better outcome of HPV-associated HNSCC raises the question about the best methodologies to distinguish between HPV and non-HPV-associated SCC. However, no consensus has been reached on the optimal way to identify HPV-associated SCC and ancillary studies have utilised many different methodologies, including HPV polymerase chain reaction testing, HPV in situ hybridization analysis, immunohistochemical staining for p16, and newer techniques that are currently under investigation. The objective of this review is to explain and give examples of various techniques of HPV detection highlighting how they might be used clinically. Although currently insufficiently specific due to the possibility of HPV infection originating at other sites, methodologies utilising serum and plasma to measure HPV infection will also be described, mostly for their potential future development and use. Finally, DNA/RNA microarray platforms will be briefly summarized for their capacity to identify the profile of molecular changes in any particular HPV+/HPV- cancer. In this way, it is expected to be possible to correlate the appropriate transcriptome-based diagnosis to the patients' specific cancer risk.
Bovine papillomavirus type 2 (BPV-2) infection has been associated with urinary bladder tumours in adult cattle grazing on bracken fern-infested land. In this study, we investigated the simultaneous presence of BPV-2 in whole blood and urinary bladder tumours of adult cattle in an attempt to better understand the biological role of circulating BPV-2. Peripheral blood samples were collected from 78 cattle clinically suffering from a severe chronic enzootic haematuria. Circulating BPV-2 DNA was detected in 61 of them and in two blood samples from healthy cows. Fifty of the affected animals were slaughtered at public slaughterhouses and neoplastic proliferations in the urinary bladder were detected in all of them. BPV-2 DNA was amplified and sequenced in 78 % of urinary bladder tumour samples and in 38.9 % of normal samples as a control. Circulating episomal BPV-2 DNA was detected in 78.2 % of the blood samples. Simultaneous presence of BPV-2 DNA in neoplastic bladder and blood samples was detected in 37 animals. Specific viral E5 mRNA and E5 oncoprotein were also detected in blood by RT-PCR and Western blot/immunocytochemistry, respectively. It is likely that BPV-2 can persist and be maintained in an active status in the bloodstream, in particular in the lymphocytes, as a reservoir of viral infection that, in the presence of co-carcinogens, may cause the development of urinary bladder tumours. INTRODUCTIONBovine papillomaviruses (BPVs) are species-specific, double-stranded DNA viruses responsible for cutaneous and mucosal neoplastic lesions. They are small non-enveloped viruses with an icosahedral capsid. Their open reading frames (ORFs) are divided into early (E) and late (L) regions. The early region encodes non-structural proteins E1 to E7, of which, E5, E6 and E7 are known to be oncoproteins. The late region encodes structural proteins L1 and L2 forming the capsid. Bovine papillomavirus type 2 (BPV-2) is classified in the genus Deltapapillomavirus, species 4, the biological properties of which are characterized by the induction of fibropapillomas in cattle and sarcoids in equids (Brandt et al., 2008;Chambers et al., 2003;de Villiers et al., 2004). BPV-2 infection in the presence of environmental carcinogens, such as ptaquiloside (PT) of bracken fern (Pteridium aquilinum), has been associated with urinary bladder neoplastic lesions in adult cattle, in which chronic enzootic haematuria (CEH) is the most important clinical sign (Campo, 1997; Campo et al., 1992;Hopkins, 1986).The effect of the route of viral infection, and the synergistic relationship between BPV-2 and immunosuppressive and oncogenic compounds present in the bracken fern in the malignant progression of bladder lesions (Campo, 1997; Campo et al., 1992; Jarrett et al., 1978;Reddy & Fialkow, 1983;Stocco dos Santos et al., 1998) are not well-known, thus deserving further investigations.To date, the BPV-2 genome has been detected in lymphocytes during latent papillomavirus infection in cattle (Campo et al., 1994). In addition, the occurrence of horiz...
Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.
Bovine papillomavirus type 2 (BPV-2) is an oncogenic virus infecting both epithelial and mesenchymal cells. Its life cycle, similar to other papillomaviruses (PVs), appears to be linked to epithelial differentiation. Human and bovine PVs have been known to reside in a latent, episomal form in PBMCs; therefore, it is believed that blood cells, like all mesenchymal cells, function as non-permissive carriers. Here, for the first time in veterinary and comparative medicine, the BPV-2 E5 oncoprotein and the major structural L1 capsid protein, known to be expressed only in productive infections, were shown to occur in defined subsets of PBMCs. E5 oncoprotein was detected in sorted T-and B-cells as well as in monocytes by flow cytometry and Western blot analysis. However, CD4 + and CD8 + lymphocytes appeared to be the main circulating targets of the virus, thus possibly representing the most important reservoir of active BPV-2 in blood. L1 protein was identified by flow cytometry in a population of blood cells recognized as lymphocytes by morphological scatter properties. Western blot analysis was performed on lysates obtained from the sorted subpopulations of PBMCs and detected L1 protein in CD4 + and CD8 + cells only. Thus, this study showed that CD4 + and CD8 + lymphocytes are permissive for BPV-2 and are new, hitherto unknown sites of productive PV infection. In light of these observations, the life cycle of PVs needs to be revisited to gain novel insights into the epidemiology of BPV infection and the pathogenesis of related diseases. INTRODUCTIONBovine papillomaviruses (BPVs) are a heterogeneous group of viruses responsible for tumours of the skin, genital and paragenital area, eye, upper gastrointestinal tract and urinary bladder (IARC, 2007). BPVs, like all other papillomaviruses (PVs), are usually strictly species specific. However, cases of cross-species infection are known to occur. BPV type 1 (BPV-1) and BPV-2, belonging to the genus Deltapapillomavirus (de Villiers et al., 2004), are responsible for infections in equids resulting in sarcoids (Chambers et al., 2003;Trenfield et al., 1985), as well as in bison and water buffaloes leading to warts (Literák et al., 2006;Silvestre et al., 2009). In addition, a variant of BPV-8, classified in the genus Epsilonpapillomavirus, also causes papillomas of the skin in bison (Tomita et al., 2007). More recently, it has been suggested that BPVs could be responsible for cutaneous sarcoids in cats and captive African lions (Munday & Knight, 2010;Orbell et al., 2010).BPV-1 and -2 are closely related serotypes (Shafti-Keramat et al., 2009) and can infect both epithelial and mesenchymal cells. Similar to other PVs, BPV-1/-2 replication and virion production are confined to the epithelial region of the lesions, whilst infection of mesenchymal cells appears to be non-productive (Campo, 2006;Shafti-Keramat et al., 2009).BPV-2 is known to play a central role in bladder carcinogenesis of adult cattle reared on pasturelands rich in bracken fern. In these animals, tumours of the u...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.